EyePoint, Inc.
Key Metrics
Market Snapshot
About
EyePoint Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing therapeutics for serious eye disorders. The company's proprietary Durasert technology platform enables sustained, controlled release of medication directly into the eye, providing long-term therapeutic effect from a single administration. EyePoint markets YUTIQ for chronic non-infectious uveitis and DEXYCU for post-surgical inflammation, while developing additional product candidates for retinal diseases including wet age-related macular degeneration and diabetic macular edema. The company's approach aims to reduce treatment burden for patients with chronic eye conditions.